<DOC>
	<DOCNO>NCT00003136</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . PURPOSE : Phase I/II trial study effectiveness amifostine , carboplatin cyclophosphamide , follow peripheral stem cell transplantation , treat patient epithelial ovarian cancer primary peritoneal cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Peripheral Stem Cell Transplantation Treating Patients With Epithelial Ovarian Cancer Primary Peritoneal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose high dose carboplatin fix dose high dose cyclophosphamide amifostine pretreatment , peripheral blood stem cell rescue patient ovarian epithelial cancer . II . Monitor engraftment kinetics granulocyte platelet recovery . III . Determine toxic effect regimen patient population . IV . Document response patient population regimen term time progression , event free survival , overall survival . OUTLINE : This dose escalation study . Patients undergo apheresis 2-4 day mobilize peripheral blood stem cell ( PBSC ) . They receive amifostine IV 15 minute . Fifteen minute later , carboplatin administer 30 minute day -6 -3 . Cyclophosphamide IV administer 1 hour carboplatin infusion complete day -6 -4 . PBSC infuse day 0 . Filgrastim ( G-CSF ) administer begin day 4 . Cohorts 3-6 patient treat dose level . At least 15 day must pass day PBSC infusion next dose escalation . The dose limiting toxicity ( DLT ) define dose produce grade 3 4 nonhematologic toxicity 2 6 patient . The maximum tolerated dose ( MTD ) define one dose level DLT dose . At least 6 patient treated MTD . Patients follow monthly 6 month , every 2-3 month 1 year , annually death . PROJECTED ACCRUAL : This study accrue 28 patient 2 year .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Amifostine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven ovarian epithelial cancer primary peritoneal carcinoma No tumor low malignant potential Chemotherapy sensitive disease Relapse great 6 month complete response chemotherapy Partial response recent chemotherapy No 3 prior chemotherapy regimens Evidence refractory recurrent disease elevate CA125 primary surgery chemotherapy ; persistent disease need still present No brain metastasis PATIENT CHARACTERISTICS : Age : 65 Performance status : GOG 0 1 Life expectancy : Not specify Hematopoietic : WBC great 2500/mm3 Platelet count great 100,000/mm3 Hepatic : Bilirubin normal Renal : Creatinine clearance least 50 mL/min Cardiovascular : Normal radionuclide cardiac scan ejection fraction great 45 % OR Normal leave ventricular function echocardiogram OR Cardiac clearance Cardiology service Pulmonary : DLCO great 50 % predict Other : Not pregnant Hepatitis B C negative HIV1 negative PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>primary peritoneal cavity cancer</keyword>
</DOC>